Monday, 01 June 2020


Novo Nordisk launches a new obesity treatment on World Obesity Day

09 October 2018 | News

By activating areas of your brain that regulate appetite, Saxenda increases the feelings of fullness and satiety, which can lead to lower calorie intake and weight loss.

Singapore – Novo Nordisk announced the availability of Saxenda (liraglutide 3.0 mg) in Singapore. Saxenda is an Health Sciences Authority (HSA)-approved, prescription injectable medicine that, when used along with a low-calorie meal plan and increased physical activity, helps adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/mto <30 kg/m²) with at least one weight-related medical problem (such as high blood pressure, high cholesterol, or type 2 diabetes or, prediabetes, or obstructive sleep apnea) to lose weight.

Singapore is feeling the weight of obesity on its shoulders with 10.8% of Singaporean adults aged 18-69 being obese, according to the National Health Survey conducted by the Ministry of Health (MOH) in 2010. This is one and a half times the figure just 10 years ago. Additionally, about 1.7 million adults are at a risk of developing obesity-related diseases. 6 in 10 of them are either pre-diabetic or suffering from chronic conditions, such as diabetes, heart disease or hypertension. The Health Promotion Board predicts that the prevalence of obesity in Singapore could increase to 15% by 2024.

 “Sitting is the new smoking, with the increase in sedentary lifestyle and unhealthy food options, obesity has become a common problem. It is a chronic medical condition that can cause numerous non-communicable diseases such as type 2 diabetes, cardiovascular complications, high blood pressure and even cancers. Any obese person who loses just 5-10% of their body weight will have a remarkable improvement in health.” said Dr Tham Kwang Wei, President of the Singapore Association for the Study of Obesity (SASO).

Saxenda has a unique mechanism of action that is similar to a hormone that the human body produces naturally to regulate appetite, known as glucagon-like-peptide (GLP-1). By activating areas of your brain that regulate appetite, Saxenda increases the feelings of fullness and satiety, which can lead to lower calorie intake and weight loss.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account